Newsroom
Friday, November 12, 2021 - New program brings more treatment options to patients with colorectal cancer
Physicians with UAB Medicine, O'Neal Comprehensive Cancer Center, and the University of Alabama at Birmingham Heersink School of Medicine have launched a new Hepatic Artery Infusion Pump Program — the only program of its type in Alabama — to offer more treatment options to patients with colon or rectal cancer that has spread to the liver. University of Alabama at Birmingham
Sunday, June 20, 2021 - First in region targeted liver cancer therapy gives patients new hope
One of the first patients in the region to undergo a targeted cancer therapy directed at the liver through a pump implanted under the skin has been declared cancer-free. UCDavis
Tuesday, June 1, 2021 - FDA approves manufacture of Intera 3000 Hepatic Arterial Infusion Pump
Intera Oncology is proud to announce that the FDA has approved the manufacture of the Intera 3000 Hepatic Artery Infusion (HAI) Pump for HAI therapy for patients with colorectal cancer and cholangiocarcinoma. The Intera 3000HAI Pump is now the only FDA-approved pump for HAI. “We formed Intera Oncology to bring this pump back to market after it was discontinued by another company. We could not let those who stood to benefit from HAI therapy go without that option,” said Michael Gaisford, president and CEO of Intera Oncology. “We are thrilled that we have accomplished our mission and that HAI therapy will be available to those who need it.”
Sunday, April 18, 2021 - Chemotherapy pump helps people with metastatic liver cancer live longer
A chemotherapy infusion pump is giving more time to people whose metastatic colorectal cancer has spread to the liver and who may have been told they are out of options. Duke Health surgical oncologists were the first to implant the Hepatic Artery Infusion (HAI) pump after it received FDA approval. Duke Health
Friday, March 1, 2019 - Michael Gaisford joins Intera Oncology President and CEO
Michael Gaisford has been named CEO of Intera Oncology, a medical device company dedicated to ensure Hepatic Artery Infusion therapy is available to any patient who could benefit from it. Gaisford brings 15 years’ experience leading strategy, marketing, and product management teams. Prior to Intera, Gaisford was Director of Marketing for Stratasys Healthcare Solutions where he oversaw global marketing programs across medical and dental markets. At Boston Scientific, he held positions in corporate strategy, marketing and divisional product marketing. Gaisford previously worked at Genentech, CVS/Pharmacy, and McKinsey & Company. He holds an MBA from the Tuck School of Business at Dartmouth and BS from Stanford University.
Wednesday, February 20, 2019 - Journal of American College of Surgeons discusses implication of discontinuation of HAI pump
Friday, February 1, 2019 - Intera Oncology launches to save HAI pump
Two doctors determined to resurrect a medical pump that increases survival of some patients with colorectal cancer and cholangiocarcinoma have launched Intera Oncology. Drs. Jonathan Reis and David Dove both have loved ones who benefitted from the only FDA-approved pump that delivers chemotherapy directly to the liver via “Hepatic Artery Infusion therapy” (HAI). When they found that the pump was to be discontinued, the doctors formed Intera Oncology to once again make the pump available to those who may benefit from it.
Wednesday, April 25, 2018 - A lifesaving pump for cancer patients is being phased out
A medical device that can add years to the lives of cancer patients is about to become unavailable, because its manufacturer has decided to stop producing it. New York Times